Interv Akut Kardiol. 2005;4(4):245-247

BLEEDING AND THROMBOTIC COMPLICATION OF PRIMARY PCI

Ivo Bernat1, Aleš Kroužecký2, Jiří Klečka3, Jiří Ferda4, Antonín Fikrle5
1 I. Interní klinika, kardiologické oddělení, FN Plzeň
2 MJIP I. interní kliniky, FN Plzeň-Lochotín
3 Chirurgická klinika FN Plzeň
4 Radiodiagnostická klinika FN Plzeň
5 Oddělení nukleární medicíny FN Plzeň

At present major bleeding is a complication of PCI in less than 5 % and subacute stent thrombosis in less than 2 % in average. We describe life threatening bleeding after primary PCI followed by subacute stent thrombosis after necessary reduction of antithrombotic treatment. Complex therapy led to successful management of both complications, more than one year follow up has been uncomplicated. The definitive infarct size and functional parameters of the left ventricle were evaluated by ECG-gated SPECT imaging.

Keywords: Key words: primary PCI, major bleeding, subacute thrombosis.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bernat I, Kroužecký A, Klečka J, Ferda J, Fikrle A. BLEEDING AND THROMBOTIC COMPLICATION OF PRIMARY PCI. Interv Akut Kardiol. 2005;4(4):245-247.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Serruys P, Jaegere P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495. Go to original source... Go to PubMed...
    2. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998: 1665-1671. Go to original source... Go to PubMed...
    3. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991; 83: 148-161. Go to original source... Go to PubMed...
    4. Cutlip DE, Baim DS, HoKK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-1971. Go to original source... Go to PubMed...
    5. Reynolds MR, Rinaldi MJ, Pinto DS, Cohen DJ. Current clinical characteristics and economic impact of subacute stent thrombosis. J of Invasive Cardiol 2002; 14: 364-368.
    6. Rinaldi MJ, Piana RN, Valuto RP, et al. Do GP IIb/III inhibitors reduce stent thrombosis? Results of a multicenter study (Abstr). Circulation 2001: 104.
    7. Serruys PW, Unger F, Sousa JF, et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124. Go to original source... Go to PubMed...
    8. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29: 6-12. Go to original source... Go to PubMed...
    9. Aguilar OM, Levine GN. High-risk percutaneous coronary interventions (Chapter 9). In: Kern et al. The Interventional Cardiac Cathetrization Handbook (Second Edition), London, UK: Mosby; 2004. Go to original source...
    10. Pate G, Webb JG. Preventing subacute thrombosis. J Invasive Cardiol. 2002; 14: 369-370. Go to original source... Go to PubMed...
    11. Quinn MW, Dillard TA. Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. Chest 1999; 116: 257-260. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.